Myogenic vasoconstriction requires G12/G13 and LARG to maintain local and systemic vascular resistance

  1. Ramesh Chennupati
  2. Angela Wirth
  3. Julie Favre
  4. Rui Li
  5. Rémy Bonnavion
  6. Young-June Jin
  7. Astrid Wietelmann
  8. Frank Schweda
  9. Nina Wettschureck
  10. Daniel Henrion
  11. Stefan Offermanns  Is a corresponding author
  1. Max Planck Institute for Heart and Lung Research, Germany
  2. University of Heidelberg, Germany
  3. UMR CNRS 6015 - INSERM 1083, Université d'Angers, France
  4. University of Regensburg, Germany

Abstract

Myogenic vasoconstriction is an autoregulatory function of small arteries. Recently, G-protein-coupled receptors have been involved in myogenic vasoconstriction, but the downstream signalling mechanisms and the in-vivo-function of this myogenic autoregulation are poorly understood. Here, we show that small arteries from mice with smooth muscle-specific loss of G12/G13 or the Rho guanine nucleotide exchange factor ARHGEF12 have lost myogenic vasoconstriction. This defect was accompanied by loss of RhoA activation, while vessels showed normal increases in intracellular [Ca2+]. In the absence of myogenic vasoconstriction, perfusion of peripheral organs was increased, systemic vascular resistance was reduced and cardiac output and left ventricular mass were increased. In addition, animals with defective myogenic vasoconstriction showed aggravated hypotension in response to endotoxin. We conclude that G12/G13- and Rho-mediated signaling plays a key role in myogenic vasoconstriction and that myogenic tone is required to maintain local and systemic vascular resistance under physiological and pathological condition.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1-5.

Article and author information

Author details

  1. Ramesh Chennupati

    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Angela Wirth

    Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Julie Favre

    Laboratoire MITOVASC, UMR CNRS 6015 - INSERM 1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Rui Li

    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Rémy Bonnavion

    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Young-June Jin

    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Astrid Wietelmann

    Scientific Service Group Nuclear Magnetic Resonance Imaging, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Frank Schweda

    Institute of Physiology, University of Regensburg, Regensburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Nina Wettschureck

    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Daniel Henrion

    Laboratoire MITOVASC, UMR CNRS 6015 - INSERM 1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Stefan Offermanns

    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    For correspondence
    stefan.offermanns@mpi-bn.mpg.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8676-6805

Funding

Max-Planck-Gesellschaft (Open-access funding)

  • Stefan Offermanns

This study was funded by the Max Planck Society.

Ethics

Animal experimentation: All animal care and use procedures in this study were approved by the local authorities (protocol numbers: B2-1031, B2-1166, B2-1069 Regierungspräsidia Karlsruhe and Darmstadt).

Reviewing Editor

  1. Mark T Nelson, University of Vermont, United States

Publication history

  1. Received: June 16, 2019
  2. Accepted: September 24, 2019
  3. Accepted Manuscript published: September 24, 2019 (version 1)
  4. Version of Record published: October 4, 2019 (version 2)

Copyright

© 2019, Chennupati et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,409
    Page views
  • 209
    Downloads
  • 16
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ramesh Chennupati
  2. Angela Wirth
  3. Julie Favre
  4. Rui Li
  5. Rémy Bonnavion
  6. Young-June Jin
  7. Astrid Wietelmann
  8. Frank Schweda
  9. Nina Wettschureck
  10. Daniel Henrion
  11. Stefan Offermanns
(2019)
Myogenic vasoconstriction requires G12/G13 and LARG to maintain local and systemic vascular resistance
eLife 8:e49374.
https://doi.org/10.7554/eLife.49374

Further reading

    1. Cell Biology
    Danielle B Buglak, Pauline Bougaran ... Victoria L Bautch
    Research Article

    Endothelial cells line all blood vessels, where they coordinate blood vessel formation and the blood-tissue barrier via regulation of cell-cell junctions. The nucleus also regulates endothelial cell behaviors, but it is unclear how the nucleus contributes to endothelial cell activities at the cell periphery. Here, we show that the nuclear-localized linker of the nucleoskeleton and cytoskeleton (LINC) complex protein SUN1 regulates vascular sprouting and endothelial cell-cell junction morphology and function. Loss of murine endothelial Sun1 impaired blood vessel formation and destabilized junctions, angiogenic sprouts formed but retracted in SUN1-depleted sprouts, and zebrafish vessels lacking Sun1b had aberrant junctions and defective cell-cell connections. At the cellular level, SUN1 stabilized endothelial cell-cell junctions, promoted junction function, and regulated contractility. Mechanistically, SUN1 depletion altered cell behaviors via the cytoskeleton without changing transcriptional profiles. Reduced peripheral microtubule density, fewer junction contacts, and increased catastrophes accompanied SUN1 loss, and microtubule depolymerization phenocopied effects on junctions. Depletion of GEF-H1, a microtubule-regulated Rho activator, or the LINC complex protein nesprin-1 rescued defective junctions of SUN1-depleted endothelial cells. Thus, endothelial SUN1 regulates peripheral cell-cell junctions from the nucleus via LINC complex-based microtubule interactions that affect peripheral microtubule dynamics and Rho-regulated contractility, and this long-range regulation is important for proper blood vessel sprouting and junction integrity.

    1. Cell Biology
    Agustin Leonardo Lujan, Ombretta Foresti ... Vivek Malhotra
    Research Article Updated

    We show that TANGO2 in mammalian cells localizes predominantly to mitochondria and partially at mitochondria sites juxtaposed to lipid droplets (LDs) and the endoplasmic reticulum. HepG2 cells and fibroblasts of patients lacking TANGO2 exhibit enlarged LDs. Quantitative lipidomics revealed a marked increase in lysophosphatidic acid (LPA) and a concomitant decrease in its biosynthetic precursor phosphatidic acid (PA). These changes were exacerbated in nutrient-starved cells. Based on our data, we suggest that TANGO2 function is linked to acyl-CoA metabolism, which is necessary for the acylation of LPA to generate PA. The defect in acyl-CoA availability impacts the metabolism of many other fatty acids, generates high levels of reactive oxygen species, and promotes lipid peroxidation. We suggest that the increased size of LDs is a combination of enrichment in peroxidized lipids and a defect in their catabolism. Our findings help explain the physiological consequence of mutations in TANGO2 that induce acute metabolic crises, including rhabdomyolysis, cardiomyopathy, and cardiac arrhythmias, often leading to fatality upon starvation and stress.